Literature DB >> 1171662

Pharmacological analysis of a new anorexic substance: 5-hydroxy-5(4'-chlorophenyl)-2, 3-dihydro-5H-imidazo-(2, 1-a) isoindole (Mazindol).

J H Gogerty, C Penberthy, L C Iorio, J H Trapold.   

Abstract

5-Hydroxy-5-(4'-chlorophenyl-2, 3-dihydro-5H-imidazo (2, 1-a)isoindole (mazindol), a novel tricyclic compound, has been shown to suppress food consumption in rats at doses causing weak central stimulation and little effects on blood pressure or heart rate. The substance produces dose-related decreases in the consumption of orange juice in cebus monkeys trained on an operant behavior schedule. The compound did not alter cardiac or pulmonary hemodynamics in the anesthetized dog but provided potentiation of norepinephrine pressor responses. Mazindol also demonstrated potent but incomplete antagonism of reserpine-induced hypothermia in mice, antagonism of tetrabenazine catalepsy in rats, and suppression of mouse-killing behavior of rats. Suppression of mouse-killing was reduced by lesions placed in the septal area of the brain. Brain monoamine oxidase or catechol-o-methyl-transferase activities were not altered, although preliminary experiments showed that mazindol reduced uptake of norepinephrine in brain tissue.

Entities:  

Mesh:

Substances:

Year:  1975        PMID: 1171662

Source DB:  PubMed          Journal:  Arch Int Pharmacodyn Ther        ISSN: 0003-9780


  7 in total

1.  Some effects of mazindol on the metabolism of monoamines in the rat brain [proceedings].

Authors:  K G Charlton; M F Sugrue
Journal:  Br J Pharmacol       Date:  1976-10       Impact factor: 8.739

2.  The anorectic action of mazindol.

Authors:  K F Sweeney
Journal:  Ir J Med Sci       Date:  1978-08       Impact factor: 1.568

3.  Psychostimulant self-administration by beagle dogs in a progressive-ratio paradigm.

Authors:  M E Risner; D L Silcox
Journal:  Psychopharmacology (Berl)       Date:  1981       Impact factor: 4.530

4.  Mazindol anorexia is mediated by activation of dopaminergic mechanisms.

Authors:  Z L Kruk; M R Zarrindast
Journal:  Br J Pharmacol       Date:  1976-11       Impact factor: 8.739

5.  Effect of mazindol on brain dopamine turnover in spiperone-treated rats.

Authors:  R W Fuller; H D Snoddy
Journal:  J Neural Transm       Date:  1979       Impact factor: 3.575

6.  Amphetamine, mazindol, and fencamfamin in narcolepsy.

Authors:  J Shindler; M Schachter; S Brincat; J D Parkes
Journal:  Br Med J (Clin Res Ed)       Date:  1985-04-20

7.  Pilot Phase II study of mazindol in children with attention deficit/hyperactivity disorder.

Authors:  Eric Konofal; Wei Zhao; Cédric Laouénan; Michel Lecendreux; Florentia Kaguelidou; Lila Benadjaoud; France Mentré; Evelyne Jacqz-Aigrain
Journal:  Drug Des Devel Ther       Date:  2014-12-01       Impact factor: 4.162

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.